A Helpful Suite of Clinical Resources for Your Practice
Access clinical tools for use with patients as well as multimedia resources providing information on diagnosis of hepatic encephalopathy (HE) and reducing the risk of overt HE recurrence in adults with XIFAXAN.
Clinical Tools
HE Symptom Assessment Checklist
A checklist for patients or caregivers to record common symptoms of hepatic encephalopathy. Share with your patients and/or caregivers prior to or at their visit to help them identify when to access immediate care or to facilitate a more productive discussion about their symptoms at their next appointment.
Download PDF >Educational Resources
XIFAXAN and AASLD/EASL Hepatic Encephalopathy Practice Guidelines
A snapshot of the latest AASLD guidelines on the management of overt hepatic encephalopathy (HE). XIFAXAN earned AASLD/EASL’s highest possible recommendation* (GRADE I,A,1) as an add-on therapy to lactulose to reduce the risk of overt HE recurrence after a patient has a recurrence while on lactulose alone.1
Download PDF >
Patient Profile: 62-Year-Old Female With Overt HE
Portrays a patient with cirrhosis diagnosed with an initial episode of overt hepatic encephalopathy (HE) when presenting to her gastroenterologist for routine monitoring; she subsequently presents with another overt HE episode. Consult this profile to help recognize patients for whom XIFAXAN may be an appropriate therapy.
Download PDF >
Patient Profile: 58-Year-Old Male With Recurrent Overt HE
A profile portraying a patient with cirrhosis diagnosed with recurrent overt hepatic encephalopathy (HE) when presenting to his gastroenterologist for routine monitoring. Consult this profile to help recognize patients for whom XIFAXAN may be an appropriate therapy.
Download PDF >*Per the GRADE System for Evidence: Grade I=randomized, controlled trials; A=evidence is “high quality,” and further research is very unlikely to change our confidence in the estimated effect; and 1=recommendation is “strong,” with factors influencing strength of recommendation including the quality of evidence, presumed patient-important outcomes, and costs.1
XIFAXAN Quick Support & Access (QSA) Plugin and Order Set Kit
XIFAXAN Quick Support & Access (QSA) Plugin and Order Set Kit
Help standardize care within your workflow to help identify and manage patients living with overt hepatic encephalopathy. With the XIFAXAN QSA plugin, you can integrate important forms and resources into your organization’s workflow and have these resources at your fingertips.
Access XIFAXAN QSAClinical Tools
XIFAXAN Dosing for Overt HE
Review the recommended dosing for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for IBS-D in adults. Refer to this dual-indication card for general XIFAXAN dosing – includes the ICD-10 code* for overt HE.
Download PDF >
XIFAXAN Prior Authorization Road Map
Step-by-step guide for completing prior authorization (PA) requirements for patients prescribed XIFAXAN, including common reasons for PA denials and guidance for Letters of Medical Necessity when needed. Download for guidance on PA requests, as well as information on electronic submissions with CoverMyMeds.
Download PDF >
XIFAXAN Savings Card
Most eligible† patients with commercial insurance and coverage for XIFAXAN may pay as little as $0 for their XIFAXAN prescription. Maximum benefits and other restrictions apply.
Get savings card >Educational Resources
Spotlight on Medication Adherence
Overview of the importance of medication adherence for patients receiving long-term therapy. Refer to this guide for helpful information when prescribing XIFAXAN for the reduction in risk of overt hepatic encephalopathy recurrence in adults.
Download PDF >
XIFAXAN Product Details
Core information on XIFAXAN for the treatment of IBS-D in adults and for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. Provides an overview of HE, including screening criteria and the impact of overt HE on cognition and patients’ health. Core efficacy and safety data for XIFAXAN, recommended dosing and information on insurance coverage are also included. Obtain core product details about XIFAXAN in one informational brochure.
Download PDF >
Help your eligible† patients save on XIFAXAN.
$0 for most eligible,† commercially insured patients with coverage for XIFAXAN. Maximum benefits and other restrictions apply.
Request Samples of XIFAXAN for Overt HE*The ICD-10 Codes and all other patient-access-related information are provided for informational purposes only. It is the treating physician's responsibility to determine the proper diagnosis, treatment and applicable ICD-10 Code. Salix Pharmaceuticals does not guarantee coverage or reimbursement for the product.
†Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.